The family of DNA gyrase inhibitors comprises two types of molecules: those which inhibit subunit A (quinolones) and those which inhibit subunit B (coumermycin, novobiocin, chlorobiocin).
The "first generation" of quinolones comprise nalidixic acid, cinoxacin, pipemidic acid, oxolinic acid, flumequine, and acrosoxacin and are indicated primarily for the treatment of urinary tract infections. The "second generation" comprises recently developed molecules of clinical interest in the treatment of systemic infections (pefloxacin, norfloxacin, enoxacin, ofloxacin, ciprofloxacin, fleroxacin, lomefloxacin). These agents are characterized by their enhanced in vitro activities against gram-negative aerobes and improved intestinal absorptions.
Enoxacin is a new fluorinated quinolone with high in vitro activity. Available studies indicate that it is effective in the management of infections caused by susceptible organisms (4, 9) .
The influence of renal failure on the pharmacokinetics of enoxacin given orally has been studied previously (1, 7), but not following intravenous (i.v.) administration. Furthermore, the disposition of the major metabolite of enoxacin, oxoenoxacin, in patients with renal impairment has not been described.
The purpose of this study was to evaluate the pharmacokinetics of i.v. administered enoxacin and its oxometabolite in patients with different degrees of renal impairment. * Corresponding author.
MATERIALS AND METHODS
The protocol for this study followed the guidelines of the Declaration of Helsinki and was reviewed by the local ethical committee. Each patient gave informed consent.
Patients. Twenty-three patients (age, 19 to 87 years) with various degrees of renal impairment were enrolled in this study. Patients were categorized prior to the administration of enoxacin into five classes according to the measured creatinine clearances, which were based on 24-h urine collections. The following classes were defined (number of patients): 1, patients on chronic hemodialysis (four patients); 2, creatinine clearance, <15 ml/min (four patients); 3, creatinine clearance, 15 to 30 ml/min (six patients); 4, creatinine clearance, 30 to 60 ml/min (four patients); 5, creatinine clearance, >60 ml/min (five patients).
The exclusion criteria were pregnant or lactating women; hepatic enzymes twice the upper limit of normal or serum bilirubin levels of >1 mg/dl; patients with an allergy to any quinolone agent; patients who were on concomitant antibacterial therapy or who received any antibiotic during the previous week; and patients who weighed less than 40 De- troit, Mich.) diluted in 100 ml of 5% glucose in water. The dose was given as a constant-rate infusion over 1 h through the antecubital vein by using an infusion pump. All four patients in the dialysis group were studied twice while they were off dialysis; three of these patients were also studied during dialysis. The interval between studies done while patients were on and off dialysis was at least 24 h. Dialysis was initiated 3 h after drug administration. Clinical and laboratory data. Base-line clinical and laboratory data were taken within 24 h prior to the start of the study and again on completion of the study. The following data were obtained: patient medical history and physical examination; 02-microglobulin (serum and urine); complete blood count with differential; serum urea and creatinine; serum glutamic oxalacetic transaminase, serum glutamic pyruvic transaminase, total bilirubin, and alkaline phosphatase; total serum protein or serum albumin; erythrocyte sedimentation rate; serum electrolytes; and creatinine clearance.
Blood sampling times. Figure 1 depicts mean serum concentration-time curves for enoxacin for each of the five patient groups studied. Overall, reduced renal function was associated with higher and more prolonged enoxacin concentrations. Table 2 summarizes the pharmacokinetics of enoxacin in each of the five patient groups. Average peak concentrations in each group ranged between 4.7 and 7.1 mg/liter; there was no statistically significant difference between groups. At 12 h, enoxacin concentrations in serum were significantly higher in groups 2 and 3 than those observed in group 5. Figure 2 depicts the linear correlation between creatinine clearance and total, renal, and nonrenal enoxacin clearances and the slope of the terminal elimination phase (Xe). Patient groups with creatinine clearances lower than 30 ml/min had mean values for total enoxacin clearance approximately one-third or less of those observed in group 5 patients (creatinine clearance, >60 ml/min); the total enoxacin clearance in groups 1 to 3 was significantly less than that observed in group 5 patients (Table 2 ; P < 0.05). The reduction in total clearance in these groups was largely due to reduced renal enoxacin clearance; however, nonrenal enoxacin clearance in patients with a creatinine clearance of less than 15 ml/min (group 2) was significantly less than that observed in group 5 patients (Table 2; P < 0.05). Interpatient variability was notably large in some patient groups; one patient in group 3 had total and nonrenal enoxacin clearances larger than the calculated mean value plus six times the standard deviation for group 3 without this patient.
Changes in enoxacin clearance were reflected in changes Enoxacin 2 (4) 3 (6) 4 (3) 5 (4) Oxoenoxacin 2 (4)
3 (6) 4 (5) 5 (4) in the half-life of the terminal elimination phase (Xi). The terminal half-life was statistically significantly prolonged in groups 1 to 3 (mean values, 13.0 to 19.9 h) compared with that in group 5 (4.5 h) (P < 0.05); interpatient variability was considerably large and did not appear to be related to the degree of decrement in renal function. The steady-state volume of distribution was not different between groups (Table 2) . Table 3 shows the urinary excretion of enoxacin. Average urinary recovery in each group ranged from 12.5 to 48.1% of the dose and decreased with worsening renal dysfunction. Oxoenoxacin pharmacokinetics. Table 4 summarizes the pharmacokinetics of oxoenoxacin in each patient group. Renal dysfunction was associated with higher concentrations of oxoenoxacin in serum. The AUCO_24 for oxoenoxacin in groups 1 to 4 differed significantly from those observed in patients with normal renal function; the higher AUCs in each patient group reflect changes in both metabolite formation as well as elimination. Plots of the ratio of oxoenoxacin: enoxacin concentration versus time were convex for all patients, indicating that the rate of metabolite formation was rate limiting in patients with normal as well as decreased renal functions (5) . Figure 3 depicts the linear relationship between creatinine clearance and renal oxoenoxacin clearance. As with enoxacin, oxoenoxacin renal clearance in groups 2 and 3 (creatinine clearance, less than 30 ml/min) was significantly less than that observed in patients with creatinine clearances exceeding 60 ml/min (Table 4) . Table 3 shows the urinary excretion of oxoenoxacin. The urinary recovery of oxoenoxacin was significantly lower in group 1 patients than in the other patients.
Hemodialysis. Figure 4 depicts enoxacin and oxoenoxacin concentrations in serum in a patient who was on and off hemodialysis. Comparison of the respective AUC,, 24 values for three patients who were on and off dialysis demonstrated that little enoxacin or oxoenoxacin was removed (Table 5) ; this was confirmed, in that low concentrations of enoxacin (.0.09 mg/liter) and oxoenoxacin (s0.28 mg/liter at 30 min to c0.09 mg/liter at 240 min) were measured in the dialysate collected over the dialysis period. An increase in oxoenoxacin concentrations (redistribution) was observed following dialysis in all three patients.
DISCUSSION
Studies in normal healthy volunteers demonstrated that enoxacin excretion is balanced between the renal and nonrenal routes. Following a single oral dose of 600 mg orally and an i.v. infusion of 400 mg, 61 and 46% of the doses, respectively, were recovered unchanged in urine (11) . Other studies have reported urinary recovery to be between 44 and 60% (1, 2, 10; M. N. Dudley, Postgrad. Med., in press).
Metabolism of enoxacin occurs on the piperazine ring to form oxo, amino, formyl, and acetyl derivatives; the major metabolite is 4-oxoenoxacin (4 to 15% of the dose excreted in urine (11, 12; Dudley, in press). Oxoenoxacin has antimicrobial activity that is 10 to 15 times less than that of the parent drug (8) .
The balance in elimination of enoxacin between the renal and nonrenal routes results in the lack of significant changes in enoxacin pharmacokinetics in patients with creatinine clearances exceeding 30 ml/min. However, in patients with creatinine clearances below 30 ml/min (i.e., groups 1 enoxacin were significantly prolonged compared with those of patients with creatinine clearances exceeding 60 ml/min. Both renal ahd, notably, nonrenal enoxacin clearances were significantly correlated with creatinine clearances. The reduction in nonrenal enoxacin clearance with reduced renal function was unexpected, but was consistent with the finding that the formation of the major metabolite oxoenoxacin remained rate limiting for all patients. Our data are in general agreement with those of previous studies of i.v. and oral enoxacin administration in elderly patients (6) and patients with renal dysfunction given a single oral dose (7) . Even in the presence of severe renal dysfunction, urinary concentrations of enoxacin exceeded the MICs for most susceptible pathogens, even up to 72 h after administration of a single dose.
In contrast to enoxacin, oxoenoxacin elimination was variably but, on average, lower in patients with milder degrees of renal dysfunction, with marked changes in renal clearance being present as the creatinine clearance fell below 30 milmin; this is consistent with the fact that renal excretion is the major route of elimination of the metabolite.
In limited studies of three patients undergoing hemodialysis, minimal amounts of enoxacin and oxoenoxacin were found in dialysates; intrapatient comparisons of the serum AUCo_24 values confirmed this low extraction. Although clearance of drug by hemodialysis could not be calculated, the low levels of the drug with expected flow rates of between 300 and 500 ml/h suggest a maximum removal of only 10 to 20 mg of drug. The low extraction of enoxacin (and other fluoroquinolones) is consistent with the finding that most of the drug is distributed to extravascular sites in the body and, thus, is not available for extraction during dialysis (4; Dudley, in press). Comparison of group mean values indicated that as the creatinine clearance falls below 30 ml/min, the daily enoxacin dose should be reduced by half; since high peak concentrations of fluoroquinolones may be linked to improved antibacterial effects and reduced selection of resistant bacteria (Dudley, in press), it is recommended that the usual dose be administered once daily (Table 6 ). With a further decrement in renal function (creatinine clearance, less than 10 to 15 ml/min), half of the usual dose should be given once daily. It should be noted, however, that accumulation of oxoenoxacin will likely occur even with these dosage alterations. The clinical consequences of oxoenoxacin accumulation are unknown.
